12/20/2014 1:03 AM IPN.PA 42.28 € (+0.94 %) Data: Yahoo Finance
Startsidan

Press Releases

  • 12/16/2014

    Ipsen’s Somatuline® Depot® is the first therapy approved by the FDA in the United States for the treatment of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors

    Ipsen’s Somatuline® Depot® is the first therapy approved by the FDA in the United States for the treatment of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors
  • 12/16/2014

    François Garnier appointed Executive Vice President, General Counsel of Ipsen

    François Garnier appointed Executive Vice President, General Counsel of Ipsen
  • 12/12/2014

    Ipsen announces that the International Breast Cancer Study Group (IBCSG) presented phase 3 results evaluating the use of ovarian suppression to adjuvant treatment with tamoxifen

    Ipsen announces that the International Breast Cancer Study Group (IBCSG) presented phase 3 results evaluating the use of ovarian suppression to adjuvant treatment with tamoxifen
  • 11/28/2014

    Ipsen announces FDA acceptance of filing for Dysport® in the treatment of upper limb spasticity in adult patients

    Ipsen announces FDA acceptance of filing for Dysport® in the treatment of upper limb spasticity in adult patients
  • 11/20/2014

    Ipsen and CNRS create the “Archi-Pex” joint research and innovation lab, in collaboration with the University of Rennes 1 and CEA

    Ipsen and CNRS create the “Archi-Pex” joint research and innovation lab, in collaboration with the University of Rennes 1 and CEA
  • 11/18/2014

    Ipsen and the Salk Institute renew their agreement for discovery research in medical sciences

    Ipsen and the Salk Institute renew their agreement for discovery research in medical sciences
  • 11/6/2014

    Otonomy obtains rights to gacyclidine data from Ipsen to support development of OTO-311 as a treatment for tinnitus

    Otonomy obtains rights to gacyclidine data from Ipsen to support development of OTO-311 as a treatment for tinnitus
  • 10/29/2014

    Ipsen: sales in the 3rd quarter and first nine months of 2014

    Ipsen: sales in the 3rd quarter and first nine months of 2014
  • 10/22/2014

    Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate

    Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate
  • 10/10/2014

    Ipsen announces positive results from phase III clinical study of Decapeptyl® (triptorelin pamoate) 11.25 mg administered by subcutaneous route to prostate cancer patients

    Ipsen announces positive results from phase III clinical study of Decapeptyl® (triptorelin pamoate) 11.25 mg administered by subcutaneous route to prostate cancer patients